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Background: Bacterial respiratory tract infections, mainly caused by Streptococcus pneumoniae, Haemophilus
influenzae and Moraxella catarrhalis are among the leading causes of global mortality and morbidity. Increased
resistance of these pathogens to existing antibiotics necessitates the search for novel targets to develop potent
antimicrobials.
Result: Here, we report a proof of concept study for the reliable identification of potential drug targets in these
human respiratory pathogens by combining high-density transposon mutagenesis, high-throughput sequencing,
and integrative genomics. Approximately 20% of all genes in these three species were essential for growth and
viability, including 128 essential and conserved genes, part of 47 metabolic pathways. By comparing these essential
genes to the human genome, and a database of genes from commensal human gut microbiota, we identified and
excluded potential drug targets in respiratory tract pathogens that will have off-target effects in the host, or disrupt
the natural host microbiota. We propose 249 potential drug targets, 67 of which are targets for 75 FDA-approved
antimicrobials and 35 other researched small molecule inhibitors. Two out of four selected novel targets were
experimentally validated, proofing the concept.
Conclusion: Here we have pioneered an attempt in systematically combining the power of high-density transposon
mutagenesis, high-throughput sequencing, and integrative genomics to discover potential drug targets at
genome-scale. By circumventing the time-consuming and expensive laboratory screens traditionally used to select
potential drug targets, our approach provides an attractive alternative that could accelerate the much needed discovery
of novel antimicrobials.Background
The World Health Organization (WHO; www.who.int)
ranks respiratory tract infections (RTI) among the ten
leading causes of global mortality. RTI are associated
with several bacterial species, of which Streptococcus
pneumoniae, Haemophilus influenzae, and Moraxella
catarrhalis are the most prevalent community-acquired
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unless otherwise stated.these species colonize mucosal surfaces of the upper air-
ways in a commensal state. Their relevance as pathogens
arises when they infiltrate and colonize the otherwise
sterile spaces in the middle ear, lung or bloodstream,
progressing to disease [2]. With the mounting inexor-
able resistance of these pathogens against several com-
monly used antimicrobials [1], discovery of new protein
targets against which new antibiotics could be developed
will highly benefit global healthcare management of RTI.
Elucidation of genes essential for bacterial growth and
viability is a prerequisite for identifying potential drug
targets [3]. Essential genes are highly conserved and are
thus considered as favourable drug targets for broad-
spectrum inhibition [4]. On the other hand, some meta-
bolic pathways constitute crucial transport and catalytic
proteins which could also form attractive drug targets.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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their biosynthetic capabilities, and instead rely on their
hosts to provide vital nutrients like amino acids, vitamins,
and nucleobases [5]. Transport systems for these nutrients
are generally conserved and indispensable for survival of
the pathogen in its host [6], making them promising drug
targets. In order to qualify as drug targets, microbial genes
should meet several requirements. First, they should be
nonhomologous to human genes to avoid drug cytotox-
icity [3]. Additionally, targets should either be completely
absent, or catalytically distinctive from genes found in host
gut commensal microbiota, whose perturbation is likely to
be detrimental to human nutrition, health, and physiology
[7]. It has been shown that antibiotic killing of commensal
microbiota facilitates proliferation, and often dominance,
of antibiotic-resistant pathogens on mucosal surfaces [8].
Lastly, candidate drug targets must be accessible by inhibi-
tors. Essential surface/membrane and secreted proteins
are particularly promising, having been successfully tar-
geted by protein drugs, and representing majority of all
known drug targets [9,10].
Previous microbial gene essentiality predictions employed
techniques generally limited in specificity and/or through-
put [11,12]. These shortcomings are alleviated by high-
throughput transposon insertion sequencing strategies,
such as Tn-seq, TraDIS, INseq, or variants thereof, which
have been applied in recent studies to comprehensively
essay gene essentiality and genetic interactions in vari-
ous bacteria [13,14]. Here, we applied Tn-seq to reliably
identify essential genes in S. pneumoniae, H. influenzae
and M. catarrhalis. Products of these genes were com-
pared against the human proteome, and the catalogue of
genes from human gut commensal microbes, to identify
and eliminate targets likely to have off-target effects in
the host or on the host’s gut microbiota. Two out of four
of the finally identified novel drug targets have been suc-
cessfully validated using existing inhibitors. This study
pioneers an integrative approach for rapid and cost-
effective identification of novel drug targets. Our findings
do not only improve the overall understanding of respira-
tory pathogens, but also serve as a proof of concept for
the robust yet underexploited approaches, combining
in silico and wet laboratory analyses in identifying anti-
microbial drug targets, as recently reviewed [15]. This ap-
proach has allowed us to identify promising drug target
leads, which after experimental validation could be poten-
tially advanced to the discovery of novel antimicrobials for
the treatment of RTI.
Methods
Bacterial genomes and gene reannotation
Whole genome sequences for S. pneumoniae TIGR4
uid57857, S. pneumoniae R6 uid57859, H. influenzae Rd
KW20 uid57771, H. influenzae 86 028NP uid58093 andM. catarrhalis BBH18 uid48809 were obtained from the
National Centre for Biotechnology Information (NCBI)
Genbank File Transfer Protocol (FTP) website (ftp://ftp.
ncbi.nih.gov/genbank/). All open reading frame (ORF)
annotations were updated using Rapid Annotation using
Subsystem Technology (RAST) [16]. In this analysis, all
locus coordinates in original Genbank genomes release
were retained without adjustments for frame-shifts.
Orthology and gene essentiality predictions
We clustered the reannotated protein sequences into
putative orthologous groups using the OrthoMCL stan-
dalone software Version 2.0.2 [17]. Most studies have
consistently deciphered essential genes under ideal con-
ditions, that is, in the richness of all necessary nutrients
and without environmental stress. For the purpose of
this study, we define the “essentiality” of a gene as its in-
dispensability under rich media conditions, unless stated
otherwise. The caveat with this approach is that essential
genes required for metabolism within the host may be
missed.
Transposon mutant libraries used were either created
in-house for this study, or obtained from literature and
reanalysed. The M. catarrhalis BBH18 marinerT7 trans-
poson mutant libraries consisting of 28,000 and 7,000
independent transformants were previously described
[18,19], and the 12,500 transformants library was gener-
ated using the previously described protocol [18]. The
40,000 transformants S. pneumoniae R6 and the 11,000
transformants H. influenzae 86 028NP library were pre-
viously described [20,21]. Libraries for the 15,000 trans-
formants S. pneumoniae R6 and H. influenzae Rd KW20
were also respectively constructed as previously de-
scribed [20,21]. The Tn-seq technology was used to
profile the relative abundance of each mutant in all li-
braries after growth as described previously [22], except
for S. pneumoniae TIGR4. Tn-seq data for S. pneumoniae
TIGR4 were obtained from literature [23]. We then per-
formed essentiality predictions for individual genes using
the in-house developed web-tool, ESSENTIALS [24],
which enabled us calculate a statistical essentiality metric
for each ORF, and precisely delineate the optimal boundary
between essential and nonessential ORFs in each of the 5
strains. Analysis data can be found at http://bamics2.cmbi.
ru.nl/websoftware/essentials/links.html.
Overrepresented metabolic pathways and subsystems
Pathways and subsystems for the strains under study
were obtained from the Kyoto Encyclopedia of Genes and
Genomes orthology, and the SEED databases respectively
[25,26]. Using a Fisher’s exact test, we performed func-
tional categories enrichment for the pathways and subsys-
tems, while incorporating the statistical essentiality value
(the fold-change value predicted by ESSENTIALS) for each
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correction and obtained q-values for corresponding
p-values [27].
Proteins subcellular localization (SCL)
The subcellular localizations (SCL) of all proteins in this
study were determined using publicly available SCL pre-
diction tools. First, we analysed all Gram-positive and
Gram-negative strains using pSORTdb version 2.0 [10]
and CELLO version 2.5 [28]. Further complementation
SCL predictions were performed using LocateP and
GnegPloc for Gram-positive and Gram-negative strains
respectively [29,30]. Additionally, the presence of integral
Gram-negative outer membrane proteins (OMP) was de-
termined using β-barrel outer membrane protein pre-
dictor (BOMP) [31]. Proteins that showed different SCL
predictions in the different predictors used were denoted
“Unknown”, together with those predicted to be of un-
known SCL by majority of the predictors used.
Selecting potential drug targets
To identify and eliminate essential genes with close un-
desirable orthologs, we performed separate unidirec-
tional protein-protein BLAST (BlastP) searches, using an
E-value cut-off of 1e-10, and minimum 70% sequence
identity over 75% sequence coverage; against the human
genome, and the metagenomics catalogue of non-
redundant human gut microbiome genes by Qin et al. [7].
Determination of antimicrobial activity
Selection of potential drug targets for in vivo validation
was mainly based on their novelty, that is, they have
not been described as targets to existing antimicrobials.
Commercial availability of inhibitory compounds without
resorting to customized chemical synthesis was also key;
all inhibitory compounds used were supplied by Sigma
Aldrich. 1-Methyluric acid, 5, 5′-Dithio-bis-(2-nitrobenzoic
Acid), and 5′-deoxyadenosine were dissolved in water
at 5 mg/ml. When necessary, the pH was neutralized
(to pH7) using 10 M NaOH solution or 1 M HCl.
Antimicrobial activity of the compounds was tested by
Kirby-Bauer/disk diffusion assay [32], by applying 10 μg
of the inhibitory compounds to 6 mm filter paper discs
at concentration ranging from 10000 to 0.05 μg/ml in
10-fold stepwise dilutions. As for (R)-6-fluoromevalonate
diphosphate 2 μl of (R)-6-fluoromevalonate diphosphate
was diluted in 1 ml of Milli-Q (MQ). 10 μl and 100 μl of
the dilution was used in separate disk diffusion assays.
Columbia III agar with 5% sheep blood medium was used
for S. pneumoniae. Brain heart infusion (BHI) agar
medium, and a combination medium of BHI, hemin,
and NAD were used for M. catarrhalis and H. influenzae
respectively. MIC calculations were performed as de-
scribed by Wiegand and colleagues [33]. Experiments wereperformed in quadruplicate, and outliers were removed
using the Grubbs test [34].
Toxicity assays on epithelial cell lines
Cellular toxicity of (R)-6-fluoromevalonate diphosphate
was tested using the CellTox Green Cytotoxicity Assay
(Promega, WI) on Detroit 562 (ATCC CCL-138) and
A549 (ATCC CCL-185) cell lines according to the man-
ufacturer’s instructions. The two cell lines were exposed
to (R)-6-fluoromevalonate diphosphate at its effective
MIC concentration of 26.6 μg/ml for 24 hours at 37°C
with 5% CO2. Fluorescence was measured on a Perkin
Elmer 1420 Victor 3 V multi-label plate reader.
Results and discussion
Genome reannotation and gene clustering
We sought to determine potential drug targets in
S. pneumoniae, H. influenzae, and M. catarrhalis follow-
ing the selection criteria outlined in Figure 1. For these
species, five strains with the required Tn-seq data were
available; S. pneumoniae strains R6 and TIGR4, H. influ-
enzae strains Rd KW20 and 86 028NP, and M. catarrhalis
strain BBH18. Altogether, genomes of these strains in their
initial annotations constituted of 10,072 open reading
frames (ORFs). These annotations were updated using
RAST to ensure consistency and comparability among
strains in subsequent analyses. This analysis resulted in
putative annotations for about 50% of all ORFs origin-
ally annotated with a hypothetical function (Table 1;
Additional file 1). Next, we clustered the updated protein
sequences using OrthoMCL, producing 1,798 orthologous
groups/clusters (OGs) with, and 2,729 without singletons
respectively (Additional file 1). This clustering of ortholo-
gous proteins allowed for the determination of species
and/or strain specific proteins, as well as determining
the metabolic potential of the strains. For example, the
“Gram-negative specific” periplasmic chaperones (SurA)
were clustered in OG_756 (cluster 756), while the “Strepto-
cocci-specific” transcriptional regulators (LytR) were
clustered in OG_2554. On the other hand, 300 OGs,
including OG_184, OG_186, OG_216, and OG_224,
among others, contained genes conserved in all the five
strains. All protein in individual OGs constituted of simi-
lar or identical functional annotations. This consistency
in grouping and annotation was observed across all
OGs, suggesting a reliable clustering. Confirmatory clus-
ters and respective annotations derived from the clusters
of orthologous genes (COGs) database were consist-
ent with our OrthoMCL clusters. Additionally, using
the OG’s, we were able to curate annotations for the
HI1586 locus in Haemophilus influenzae Rd KW20,
which was possibly misannotated in the initial release, as
an isoleucyl-tRNA synthetase instead of a NaP+P/HP+P
antiporter.
Orthology
(OrthoMCL)
Subcellular Localization
(pSORTdb, cello, locateP, GnegmPloc 
and β-barrel)
Metabolic pathways
(KEGG & SEED)
Conserved Homologs:
(MetaHIT catalogue, Human 
genome)
Potential Drug targets
Reannotation
(RAST)
Essentiality
(ESSENTIALS)
10,072 ORFs
2,729 OGs 
1,798 singletones
10,072 ORFs
705 OGs
2,147 genes
705 OGs
2,147 genes
Strain
S. pneumoniae R6
S. pneumoniae TIGR4
H. influenzae 86 028NP
H. influenzae Rd KW20
M. catarrhalis BBH18
249 OGs / 55 unique pathways
Figure 1 Schematic overview of the drug target selection criteria. Genome annotations information for S. pneumoniae R6, S. pneumoniae
TIGR4, H. influenzae 86 028NP, H. influenzae Rd KW20, and M. catarrhalis BBH18 were updated using RAST. The proteins with updated annotations
were then clustered into putative orthologous groups using OrthoMCL, and their subcellular localizations predicted in various publicly available
tools. ESSENTIALS was used to analyse various transposon mutant libraries and predict the essentiality metric for each ORF. Comparing the
ensuing essential genes with the catalogue of human gut microbial genes, as well as with the human genome helped to eliminate genes with
conserved orthologs, and subsequently prioritize potential drug targets.
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Loss of mutant readouts from a transposon library after
in vitro transposition and genetic transformation of the
wild-type isolate is a strong indicator of gene essentiality
[35]. Although some essential genes tolerate disruptive
insertions in the 3′ regions, generally, insertions in
essential genes lead to lethal phenotypes [36]. For our
analysis, mutant libraries and/or Tn-seq data were con-
structed in in-house experiments or obtained from lit-
erature (Table 1). We separately analysed the Tn-seq
datasets using ESSENTIALS [24]. This analysis resulted
in the identification of 532 essential genes in H. influen-
zae 86-028NP, representing 28% of the genome, a higher
number as compared to the other Gram-negative strains;
H. influenzae Rd KW20 and M. catarrhalis BBH18, in
which we identified 431 and 445 essential genes re-
spectively. In S. pneumonia, we identified 325 and 414
essential genes for the R6 and TIGR4 strains respect-
ively (Table 1; Additional file 1). These values showed
that on average, about 20% of all genes in the five strains
are essential. This is consistent with earlier studies which
have reported 15-25% of all genes in a genome being
essential [23,36,37].
Differences in the number of essential genes could be
explained by various factors that hamper precision intransposon mutagenesis experiments, including short gene
lengths and unsaturated transposon libraries; “saturation”
being the presence of at least one insertion in every gene.
In practice, short genes are less susceptible to disruptive
transposon insertions, hence, more likely to be misclassi-
fied as essential. In unsaturated transposon mutant librar-
ies, dispensable genes are also more likely to be devoid of
transposon insertions, and therefore misclassified as being
essential genes. The low-density transposon mutant library
(approximately 11,000 colony forming units; CFU) used
for H. influenzae 86-028NP, and a substantial number
of short genes in its genome could, therefore, explain the
apparently overestimated (532) essential genes. Relatively
saturated libraries of approximately 20,000 CFU and
40,000 CFU were used for H. influenzae Rd KW20 and
M. catarrhalis BBH18 respectively (Table 1). A rarefaction
analysis on our data confirmed that the S. pneumoniae,
M. catarrhalis, and H. influenzae Rd KW20 trans-
poson libraries approached saturation (Additional file 2).
Additionally, based on derivations of Poisson’s law, there
is a 99.6% probability that genes with a size of 1 kb are
hit in the 1.9 MbH. influenzae 86-028NP genome and
an 11,000 CFU mutant library. Similar statistics on
the 1.79 MbH. influenzae Rd KW20 genome with a
20,000 CFU mutant library shows a 99.99% probability.
Table 1 Strain genome annotation updates and essentiality predictions
Annotations update Essentiality predictions
Strain Genbankaccession
Total number
of ORFs
ORFs with hypothetical
function in genome
ORFs with hypothetical
function after RAST
Number of
insertion sitesa
Log2 fold change
cut-offb
Mutant library
size (CFU)
Number of
sequenced readsc
Total essential
genes
S. pneumoniae R6 NC003098 2,116 735 362 133,135 -6.45
40,000
8,906,301
325
4,400,836**
15,000*
5,641,892*
6,335,218*
S. pneumoniae TIGR4 NC003028 2,302 738 458 141,459 -4.43 6 × 20,000
876,181
414
855,535
825,675
1,294,187
1,241,843
1,291,425
H. Influenzae 86 028NP NC007146 1,900 456 233 138,229 -4.64 11,000
5,751,765
532
4,880,492
9,925,569
9,517,400
H. influenzae Rd KW20 NC000907 1,790 429 118 131,955 -4.59 20,000*
3,857,040*
431
3,229,286*
8,152,867*
7,724,536*
M. catarrhalis BBH18 NC014147 1,964 586 573 116,242 -4.70
28,000 3,522,998**
44512,500* 4,618,913*
7,000 4,697,209
Transposon mutant libraries and Tn-seq data prepared for this study (*), or Tn-seq data sequenced in this study from mutant libraries obtained from literature (**); otherwise, all data was obtained from literature and
reanalysed in this study.
aTotal number of possible unique transposon insertion sites in the genome; bthe computed fold change cut-off that separates essential and nonessential genes in each strain; cnumber of sequence reads generated by
the Illumina HiSeq sequencer.
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http://www.biomedcentral.com/1471-2164/15/958Therefore, H. influenzae 86-028NP could have suffered
slightly more false positive predictions due to its less satu-
rated mutant libraries.
We selected 705 OGs containing at least one essential
gene from any of the five strains for further analysis.
These essential OGs mainly consist of proteins with an-
notated functions, participating in diverse core cellular
processes, such as DNA replication, DNA transcription,
protein translation, cell wall biosynthesis, signal trans-
duction, and metabolism. Eighteen OGs, however, con-
tained conserved proteins of uncharacterized function
(Additional file 1). Functional characterization of these
genes will aid in achieving the optimal set of targets that
can be used to develop antimicrobials against RTI caus-
ing bacteria. The distribution and overlap of the essential
genes within the three species is outlined in Figure 2.
From the 705 OGs, we identified 128 OGs that consti-
tuted of genes conserved and essential in all five strains,
representing targets particularly attractive for developing
broad-spectrum antimicrobials to treat RTI, since they
encode components of basal cellular functions in respira-
tory pathogens. Importantly, collective analysis of the five
strains revealed species-specific and/or “Gram-category”
specific essential genes, best suited for narrow-spectrum or
specialized inhibition.
Essential metabolic pathways and subsystems
Functional category enrichment analyses were performed
for all KEGG metabolic pathways and the SEED subsys-
tems [25,26]. As of August 22, 2013, the KEGG database
describes 448 fully characterized pathways, which areS. pneumoniae 
•S. pneumoniae R6 (12)
•S. pneumoniae TIGR4 (62)
M. catarrhalis 
•M. catarrhalis BBH18 
H. influenzae
•H. influenzae Rd KW20 (32)
•H. influenzae 86 028NP (1)
128
125
98
117 
41
81
Figure 2 A Venn diagram showing the overlap of essential
orthologous groups among the respiratory pathogens.
Singletones are shown in brackets.further subcategorized into 262,304 reference maps for
various organisms. All KEGG characterized proteins in
the 705 essential OGs could be assigned to 84 unique
pathways. Among these, characterized proteins contained
in the 128 OGs that are conserved and essential in all
five strains could be assigned to 47 metabolic pathways
(Additional files 1 and 3). As was the case for essential
genes, the identified essential pathways specify among
other functions, core bacterial bioprocesses like mem-
brane transport, DNA replication and repair, signal
transduction, metabolism, transcription and translation,
ribosomal functions, and cellular processes including cell
motility. The SEED, an alternative to KEGG, comprehen-
sively groups genes at the level of a biological system and
its subsystems. Currently, there are approximately 1,009
characterized SEED subsystems. Use of SEED subsystems
on the essential OGs also revealed overrepresentation
of critical system processes, including those involved
in protein biosynthesis, virulence, disease and defence,
as well as metabolism of cofactors, vitamins, prosthetic
groups, pigments, fatty acids, lipids, and isoprenoids
(Table 2; Additional file 4).
Protein subcellular localization
Out of the 705 OGs selected, the majority (526) consists
of cytoplasmic proteins. Cellular localization of the other
OGs were predicted to be: 96 in the inner membrane, 11
in the outer membrane, 12 in the periplasm, and 4 in
the extracellular space. In addition, 21 OGs are non-
categorically predicted to contain membrane proteins,
whereas 35 are of unknown localizations. Of the 11 outer
membrane OGs, 7 contained β-barrels (Additional file 1).
Orthologs in human and human gut microflora
The human gut is home to microbiota whose proper
composition and functioning collectively influence hu-
man nutrition, protection against pathogens and devel-
opment of disease [7]. Perturbing this microbiota with
antibiotics could cause adverse side effects. Furthermore,
interference with human cell physiology by antibiotics as
a consequence of non-specific targeting can cause severe
cellular cytotoxicity [3], which may result in organ fail-
ure or even death. We used blastP analyses against the
human genome (Genome Reference Consortium) and
the human gut microbial gene catalogue [7], to identify
targets that would likely have off-target effects. It is
noteworthy that targets with as few as 10 matches in
the non-redundant gut microbial gene catalogue were
allowed in the final selection, as we hypothesised that
these would have no effects on the gut microbiome pre-
venting disruption of gut health. This decision was moti-
vated by the observation from our analysis that well
known targets for both clinically approved antimicro-
bials and experimental small molecule inhibitors collated
Table 2 Distribution of essential features among respiratory pathogens
Quantity in the strain
mct hin hit spn spr
Essential structural and non-coding RNAs 5 49 41 136 47
tRNA 4 18 0 12 8
rRNA 1 31 41 44 30
sRNA n/a n/a n/a 80 9
Essential Protein-coding ORFs 445 431 532 414 325
Protein of unknown functions 159 172 225 186 127
Metabolism 173 142 182 124 100
Genetic Information Processing 93 95 101 95 93
Environmental Information Processing 20 24 24 9 5
Overrepresented/essential KEGG pathways 236 437 196 307 356
Metabolism 136 221 95 171 213
Genetic Information Processing 74 177 74 128 129
Environmental Information Processing 26 38 26 8 14
Cellular Processes 0 1 1 0 0
Overrepresented/essential SEED subsystems 449 513 602 450 355
Protein metabolism 84 85 99 100 93
Cofactors, Vitamins, Prosthetic Groups, Pigments 75 61 80 29 25
Cell Wall and Capsule 47 60 78 47 30
Amino Acids and Derivatives 41 59 58 14 11
Respiration 41 16 34 8 7
Fatty Acids, Lipids, and Isoprenoids 29 36 40 26 21
RNA Metabolism 25 59 71 60 39
Carbohydrates 24 30 46 47 35
DNA Metabolism 19 37 35 45 41
Stress Response 18 17 9 10 8
Nucleosides and Nucleotides biosynthesis 17 13 11 25 9
Virulence, Disease and Defence 16 18 18 16 15
Regulation and Cell Signalling 8 4 8 6 5
Cell Division and Cell Cycle 5 18 15 17 16
The strains under study are abbreviated: mct; Moraxella catarrhalis BBH18, hin; Haemophilus influenzae Rd KW20, hit; H. influenzae 86 028NP, spn; Streptococcus
pneumoniae TIGR4, and spr; S. pneumoniae R6. Untested categories are denoted by “n/a”.
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on average fewer than 10 blast hits against the human gut
microbial gene catalogue (Additional file 1; column 20).
On the other hand, the majority of the targets with numer-
ous blast hits were aminoacyl-tRNA synthetases (aaRSs)
and ribosomal protein, including rpsL, a well-known target
that had 249 hits for pneumococci, 156 for H. influenzae,
and 151 for M. catarrhalis. One shortcoming of using
such filtering criteria is that novel targets that have
more than 10 blast hits are not effectively retained in
the final selection. Nevertheless, we identified 96 OGs
with orthologs in human, and 127 OGs with orthologs
in human gut microflora, that is, with >10 blast hits(Additional file 1). All 20 aminoacyl-tRNA synthetases
(aaRSs), essential for protein synthesis, were particularly
conserved in both human and human gut microflora.
Studies have shown that aaRSs can be selectively targeted
as most bacterial aaRSs recognize and aminoacylate only
cognate tRNA [38]. However, possible side effects are
expected from drugs targeting aaRSs. RNA molecules
and ribosomal proteins were also highly conserved in
gut microbiota and humans. Additionally, the relatively
short lengths and the presence of highly repetitive DNA in
RNA sequences also rendered their essentiality predictions
unreliable. All these molecules were therefore not included
in the final selection of drug targets. Moreover, blast
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man orthologs showed minimal sequence identities (<35%)
over short sequence coverage.
Drug targets selection and validation
We identified 249 potential drug targets in the five strains
(Additional file 5), including key enzymes in pathways such
as fatty acid biosynthesis [39-41], vitamin biosynthesis
[42-45], and isoprenoid biosynthesis pathways [46-48],
which have gained interest in drug discovery research, as
well as 67 known targets inhibited by 75 FDA-approved
antimicrobial drugs and 35 other researched small mol-
ecule inhibitors collated in the DrugBank database [49]. To
validate our target prediction, we selected four novel tar-
gets with commercially available novel inhibitors of their
predicted essential functions, that is, inhibitors not yet ap-
proved as clinical drugs and don’t require to be custom
synthesized: We tested whether exposure to these com-
pounds inhibited growth of the target organisms.
Vitamin biosynthetic pathways constitute an attractive
and largely untapped source of potential drug targets
[42,45]. For instance, thiamine (vitamin B1) in its active
form thiamine diphosphate, is indispensable for the ac-
tivity of the carbohydrate and branched-chain amino
acid metabolic enzymes [42]. Most bacteria synthesize
thiamine de novo, whereas humans depend on dietary
uptake, making the thiamine biosynthetic pathway an at-
tractive selective drug target. Folic acid (vitamin B9) is
another indispensable cofactor, whose biosynthetic path-
way was a target for sulfamidochrysoidine (prontosil);
later replaced by an improved sulphonamide drug sulf-
anilamide, the first ever antibiotic used in humans [50].
The pathway is also targeted by trimethoprim [45], an-
other clinically acknowledged chemotherapeutic agent
that acts on dihydrofolate reductase. Niacin (vitamin B3;
alternatively known as nicotinamide or nicotinic acid)
is also essential to all living cells and is biosynthetically
converted to nicotinamide adenine dinucleotide (NAD+),
a coenzyme involved in electron transport reactions in
cell metabolism processes [51]. After it was described
that niacin has therapeutic effects and it modulates va-
rious biological effects as well as NAD+ metabolism,Table 3 Drug target in vivo validation summary
Compound Amount on
disc (μg)
5,5′-dithiobis(2-nitrobenzoate) (CAS 69-78-3) 1,000
1-methyluric acid (CAS 708-79-2) 1,000
5′deoxyadenosine (CAS 4754-39-6) 1,000
(R)-6-fluoromevalonate diphosphate (CAS 2822-77-7) 1,000
(R)-6-fluoromevalonate diphosphate (CAS 2822-77-7) 100
Diameter of the clearance zone after normal incubation represents the inhibition area
Std. Dev. = Standard deviation.there has been an increased interest in the role of NAD+
biosynthetic pathway in health and disease [52]. Pros-
pects of targeting the pathway are also being explored.
We used 5, 5′-Dithiobis, 2-nitrobenzoic acid (CAS: 69-
78-3) to inhibit NAD+ kinase (EC: 2.7.1.23) - a key en-
zyme in the NADP biosynthesis which catalyses the
phosphorylation of NAD+ into NADP+. Inhibition of
growth was expected in both Gram-positive and Gram-
negative strains. However, inhibition of growth was only
observed in the disk diffusion assays for S. pneumoniae.
MIC calculations were inconclusive as they ranged from
319 to 2500 μg/ml with a large variability between assays
(Table 3).
As an essential amino acid, methionine is not synthe-
sized de novo in humans, who must rely on dietary intake.
Enzymes involved in microbial methionine biosynthesis
therefore offer highly specific and selective drug targets.
We used 1-methyluric acid (CAS: 708-79-2) to target
S-adenosylmethionine synthetase (EC: 2.5.1.6); a key
enzyme in methionine biosynthesis, whose drug target po-
tential has been explored in various pathogens [53,54].
Contrary to expectations, no growth inhibition was ob-
served in Gram-negative strains (Table 3; Figure 3):
growth inhibition was only observed in S. pneumoniae.
Since 1-methyluric acid formed a precipitate in concentra-
tions above 312 μg /ml, no MIC values could be calcu-
lated. This lack of growth inhibition in Gram-negative
strains may possibly be due to their double layered cell
walls which are less penetrable [55], or the bacteria have
expanded their resistance mechanisms to evade killing by
antimicrobials [55,56]. It is also possible that the two
Gram-negative species have alternative mechanisms for
methionine biosynthesis, further complicating screening
for effective drugs.
The microbial fatty acid synthesis (FAS) pathway is an
attractive target for drug discovery [41,57]. This pathway
is subdivided into type I and II, whereby human FAS pro-
teins predominantly belong to type I FAS, and the bac-
terial ones are predominantly type II FAS. Proteins from
the two FAS types generally possess distinctive molecular
organization of the active site allowing for selective tar-
geting [39,40]. Although Gram-positive pathogens couldMIC μg/ml; Std. Dev. [Inhibition area on disk diffusion assay]
S. pneumoniae H. influenzae M. catarrhalis
2,500; 0 [4 mm*] 781; 313 [none] 319; 303 [none]
>312.5 [6 mm] >312.5 [none] >312.5 [none]
78.1; 0 [6 mm] 205; 132 [5 mm*] 29.3; 11 [12 mm]
26.6; 11.5 [12 mm] 4,167; 1443 [none] >5,000; 0 [none]
26.6; 11.5 [4 mm*] 4,167; 1443 [none] >5,000; 0 [none]
on disk. Concentrations showing delayed growth are denoted by an asterisk (*).
Figure 3 Validation of growth inhibition using disk diffusion essays. Cell culture plate cross-sectional images showing the area of growth
inhibition for: a. M. catarrhalis in 5′deoxyadenosine, and S. pneumoniae in; b. (R)-6-fluoromevalonate diphosphate, 1-methyluric acid, d. 5, 5′-dithiobis
(2-nitrobenzoate), and e. 5′deoxyadenosine respectively.
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fatty acids; particularly unsaturated fatty acids [58,59], sev-
eral clinical and household antimicrobials targeting key
FAS enzymes, e.g. Platensimycin and Platencin have been
successfully developed [41,60]. In our analysis, we identi-
fied various genes conserved in all five strains, for example
genes in OGs 085, 143, and 653, whose products play key
roles in the FAS pathway. With 5′-Deoxyadenosine (CAS:
4754-39-6), we targeted lipoate synthase (LipA; EC:
2.8.1.8), a key enzyme in the lipoic acid metabolism [61],
using product-level inhibition. Surprisingly, we observed
growth inhibition in all three species (Figure 3; Table 3),
despite the target cluster (OG_653) comprising of ortho-
logs from only Gram-negative strains (Additional file 1).
This observations are also reflected in the MIC, which
ranged from 29.3 to 205.1 μg/ml (Table 3). A blastP com-
parison showed that the closest ortholog of the Gram-
negative LipA in S. pneumoniae is the non-lipoic pathway
enzyme fructose-6-phosphate aldolase I, sharing about 32%
sequence identity. Moreover, a comparison between LipA
and lipoate-protein ligase (LplA), the key lipoylation en-
zyme in S. pneumoniae [61], revealed that the two proteins
are non-orthologous, as they share very low sequence iden-
tity (<25%). They however have conserved domain which
may explain the observed growth inhibition.
Isoprenoids are natural products involved in many bio-
chemical functions, such as supplying quinones for the
electron transport chains, components of membranes, and
subcellular targeting and regulation [47]. Humans employ
the mevalonate pathway, whereas most microbes follow a
non-mevalonate (1-deoxy-d-xylulose 5-phosphate/2-C-me-
thyl-d-erythritol 4-phosphate) pathway. Functional roles of
key enzymes in the isoprenoid biosynthesis pathway are
well characterized, opening prospects for the discovery of
novel drug targets [46,48]. Fosmidomycin is a promising
isoprenoid-based anti-malarial drug which is currently in
clinical trials [48]. Using 6-fluoromevalonate (CAS: 2822-
77-7) to target diphosphomevalonate decarboxylase (EC:
4.1.1.33), we observed selective growth inhibition only in
S. pneumoniae as expected (Figure 3; Additional file 1;Table 3). Additionally, no effects on growth were observed
in the Gram-negative strains, which was also as expected.
We determined an average MIC of value 26.6 μg/ml
for the S. pneumoniae growth inhibition (Table 3). At
26.6 μg/ml, no toxicity was observed in cell toxicity assays
on epithelial cell lines (data not shown). Moreover, in
patent WO 1995013058 A1, no cytotoxic effects of 6-
fluoromevalonate were observed on T-lymphocytes. Pre-
vious literature also shown that 6-fluoromevalonate could
potentially function the same as statins, as they inhibit the
same pathway [62]. Diphosphomevalonate decarboxylase
could therefore be a promising target for developing novel
antibiotics against S. pneumoniae [63].
Conclusion
We have combined Tn-seq with in silico approaches to ob-
tain an insight into many essential and conserved molecular
functions, which we predicted to be unique among respira-
tory pathogens. With this combinatorial approach, we have
reliably identified 249 potential drug targets, 67 of which
are acknowledged targets for 75 FDA-approved antimicro-
bial drugs and 35 other researched small molecule inhibi-
tors [49]; we successfully validated two of the four tested
targets. Here, we propose a number of novel potential drug
targets that are a concrete lead for experimental validation.
We anticipate that future research based on this study will
eventually provide interesting targets that can be success-
fully moved to drug development. In conclusion, we have
pioneered a powerful approach, which combines microbial
gene essentiality data with robust computational tech-
niques, to comprehensively screen for antimicrobial drug
targets at genome-scale. This approach circumvents the
complex and costly laboratory screens, thus, facilitating di-
rected drugs discovery.
Availability of supporting data
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library saturation.
Additional file 3: KEGG functional categories enrichment using
fisher’s exact test. Unrepresented categories are denoted by “n/a”.
Additional file 4: The SEED functional categories enrichment using
fisher’s exact test. Unrepresented categories are denoted “n/a”.
Additional file 5: A summary of all selected potential target. This is
a summarized version of Additional file 1. OG denotes the Orthologous
cluster as determined using OrthoMCL (Additional file 1; reference 17).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FM, SH, MJ, PH, and AZ designed the research; SH and AZ supervised the
project; PB, HB, SV, and JL constructed the transposon mutant libraries; CJ
and ES performed the MIC and toxicity screens; FM and AZ analysed the
data and interpreted the results, and FM wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by funding from the European Commission FP7
Marie Curie IEF Action [274586 to AZ] and the Netherlands Genomics
Initiative Horizon Breakthrough [93518023 to PB].
Author details
1Radboud Institute for Molecular Life Sciences, Laboratory of Paediatric
Infectious Diseases, Radboud University Medical Centre, Nijmegen 6500 HB,
The Netherlands. 2Radboud Institute for Molecular Life Sciences, Centre for
Molecular and Biomolecular Informatics, Radboud University Medical Centre,
Nijmegen 6500 HB, The Netherlands. 3NIZO food research, Ede 6710 BA, The
Netherlands. 4Current address: Department of Veterinary Medicine, University
of Cambridge, Cambridge CB3 0ES, UK. 5Current address: Crucell – Johnson
and Johnson, Leiden, The Netherlands.
Received: 22 April 2014 Accepted: 23 October 2014
Published: 5 November 2014
References
1. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN: Worldwide
prevalence of antimicrobial resistance in Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Anti-
microbial Surveillance Program, 1997-1999. Clin Infect Dis 2001,
32(Suppl 2):S81–S93.
2. Lijek RS, Weiser JN: Co-infection subverts mucosal immunity in the upper
respiratory tract. Curr Opin Immunol 2012, 24:417–423.
3. Duffield M, Cooper I, McAlister E, Bayliss M, Ford D, Oyston P: Predicting
conserved essential genes in bacteria: in silico identification of putative
drug targets. Mol Biosyst 2010, 6:2482–2489.
4. Sakharkar KR, Sakharkar MK, Chow VT: A novel genomics approach for the
identification of drug targets in pathogens, with special reference to
Pseudomonas aeruginosa. In Silico Biol 2004, 4:355–360.
5. Lewis K: Multidrug resistance: Versatile drug sensors of bacterial cells.
Curr Biol 1999, 9:R403–R407.
6. Clayton RA, White O, Ketchum KA, Venter JC: The first genome from the
third domain of life. Nature 1997, 387:459–462.
7. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N,
Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H,
Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D,Linneberg A, Nielsen HB, Pelletier E, Renault P: A human gut microbial
gene catalogue established by metagenomic sequencing. Nature 2010,
464:59–65.
8. Buffie CG, Pamer EG: Microbiota-mediated colonization resistance against
intestinal pathogens. Nat Rev Immunol 2013, 13:790–801.
9. Ahram M, Springer DL: Large-scale proteomic analysis of membrane
proteins. Expert Review of Proteomics 2004, 1:293–302.
10. Yu NY, Laird MR, Spencer C, Brinkman FS: PSORTdb–an expanded, auto-
updated, user-friendly protein subcellular localization database for
Bacteria and Archaea. Nucleic Acids Res 2011, 39:D241–D244.
11. Molzen TE, Burghout P, Bootsma HJ, Brandt CT, van der Gaast-de Jongh CE,
Eleveld MJ, Verbeek MM, Frimodt-Moller N, Ostergaard C, Hermans PW:
Genome-wide identification of Streptococcus pneumoniae genes essential
for bacterial replication during experimental meningitis. Infect Immun
2011, 79:288–297.
12. Sassetti CM, Boyd DH, Rubin EJ: Comprehensive identification of
conditionally essential genes in mycobacteria. Proc Natl Acad Sci U S A
2001, 98:12712–12717.
13. van Opijnen T, Camilli A: Transposon insertion sequencing: a new
tool for systems-level analysis of microorganisms. Nat Rev Microbiol
2013, 11:435–442.
14. Barquist L, Boinett CJ, Cain AK: Approaches to querying bacterial genomes
with transposon-insertion sequencing. RNA Biol 2013, 10:1161–1169.
15. Chung BK-S, Dick T, Lee D-Y: In silico analyses for the discovery of
tuberculosis drug targets. J Antimicrob Chemother 2013, 68:2701–2709.
16. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K,
Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL,
Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD,
Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O: The RAST
Server: rapid annotations using subsystems technology. BMC Genomics
2008, 9:75.
17. Li L, Stoeckert CJ Jr, Roos DS: OrthoMCL: identification of ortholog groups
for eukaryotic genomes. Genome Res 2003, 13:2178–2189.
18. de Vries SP, Burghout P, Langereis JD, Zomer A, Hermans PW, Bootsma HJ:
Genetic requirements for Moraxella catarrhalis growth under iron-
limiting conditions. Mol Microbiol 2013, 87:14–29.
19. de Vries SP, Eleveld MJ, Hermans PW, Bootsma HJ: Characterization of the
molecular interplay between Moraxella catarrhalis and human
respiratory tract epithelial cells. PLoS One 2013, 8:e72193.
20. Burghout P, Cron LE, Gradstedt H, Quintero B, Simonetti E, Bijlsma JJE,
Bootsma HJ, Hermans PWM: Carbonic Anhydrase Is Essential for
Streptococcus pneumoniae Growth in Environmental Ambient Air.
J Bacteriol 2010, 192:4054–4062.
21. Langereis JD, Zomer A, Stunnenberg HG, Burghout P, Hermans PWM:
Nontypeable Haemophilus influenzae Carbonic Anhydrase Is
Important for Environmental and Intracellular Survival. J Bacteriol
2013, 195:2737–2746.
22. Burghout P, Zomer A, van der Gaast-de Jongh CE, Janssen-Megens EM,
Françoijs K-J, Stunnenberg HG, Hermans PWM: Streptococcus pneumoniae
Folate Biosynthesis Responds to Environmental CO2 Levels. J Bacteriol
2013, 195:1573–1582.
23. van Opijnen T, Bodi KL, Camilli A: Tn-seq: high-throughput parallel
sequencing for fitness and genetic interaction studies in microorganisms.
Nat Methods 2009, 6:767–772.
24. Zomer A, Burghout P, Bootsma HJ, Hermans PW, van Hijum SA:
ESSENTIALS: software for rapid analysis of high throughput transposon
insertion sequencing data. PLoS One 2012, 7:e43012.
25. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M: KEGG for integration
and interpretation of large-scale molecular data sets. Nucleic Acids Res
2012, 40:D109–D114.
26. Overbeek R, Begley T, Butler RM, Choudhuri JV, Chuang HY, Cohoon M,
de Crecy-Lagard V, Diaz N, Disz T, Edwards R, Fonstein M, Frank ED,
Gerdes S, Glass EM, Goesmann A, Hanson A, Iwata-Reuyl D, Jensen R,
Jamshidi N, Krause L, Kubal M, Larsen N, Linke B, McHardy AC, Meyer F,
Neuweger H, Olsen G, Olson R, Osterman A, Portnoy V: The subsystems
approach to genome annotation and its use in the project to annotate
1000 genomes. Nucleic Acids Res 2005, 33:5691–5702.
27. Storey JD, Tibshirani R: Statistical significance for genomewide studies.
Proc Natl Acad Sci U S A 2003, 100:9440–9445.
28. Yu CS, Chen YC, Lu CH, Hwang JK: Prediction of protein subcellular
localization. Proteins 2006, 64:643–651.
Mobegi et al. BMC Genomics 2014, 15:958 Page 11 of 11
http://www.biomedcentral.com/1471-2164/15/95829. Zhou M, Boekhorst J, Francke C, Siezen RJ: LocateP: genome-scale
subcellular-location predictor for bacterial proteins. BMC Bioinformatics
2008, 9:173.
30. Shen HB, Chou KC: Gneg-mPLoc: a top-down strategy to enhance the
quality of predicting subcellular localization of Gram-negative bacterial
proteins. J Theor Biol 2010, 264:326–333.
31. Berven FS, Flikka K, Jensen HB, Eidhammer I: BOMP: a program to predict
integral beta-barrel outer membrane proteins encoded within genomes
of Gram-negative bacteria. Nucleic Acids Res 2004, 32:W394–W399.
32. Bauer AW, Perry DM, Kirby WM: Single-disk antibiotic-sensitivity testing of
staphylococci: An analysis of technique and results. AMA Archives of
Internal Medicine 1959, 104:208–216.
33. Wiegand I, Hilpert K, Hancock RE: Agar and broth dilution methods to
determine the minimal inhibitory concentration (MIC) of antimicrobial
substances. Nat Protoc 2008, 3:163–175.
34. Grubbs FE: Procedures for Detecting Outlying Observations in Samples.
Technometrics 1969, 11:1–21.
35. Gawronski JD, Wong SM, Giannoukos G, Ward DV, Akerley BJ: Tracking
insertion mutants within libraries by deep sequencing and a genome-
wide screen for Haemophilus genes required in the lung. Proc Natl Acad
Sci U S A 2009, 106:16422–16427.
36. Christen B, Abeliuk E, Collier JM, Kalogeraki VS, Passarelli B, Coller JA, Fero MJ,
McAdams HH, Shapiro L: The essential genome of a bacterium. Mol Syst Biol
2011, 7:528.
37. Akerley BJ, Rubin EJ, Novick VL, Amaya K, Judson N, Mekalanos JJ: A
genome-scale analysis for identification of genes required for growth
or survival of Haemophilus influenzae. Proc Natl Acad Sci U S A 2002,
99:966–971.
38. Ochsner UA, Sun X, Jarvis T, Critchley I, Janjic N: Aminoacyl-tRNA
synthetases: essential and still promising targets for new anti-infective
agents. Expert Opin Investig Drugs 2007, 16:573–593.
39. Campbell JW, Cronan JE Jr: Bacterial fatty acid biosynthesis: targets for
antibacterial drug discovery. Annu Rev Microbiol 2001, 55:305–332.
40. Payne DJ, Warren PV, Holmes DJ, Ji Y, Lonsdale JT: Bacterial fatty-acid
biosynthesis: a genomics-driven target for antibacterial drug discovery.
Drug Discov Today 2001, 6:537–544.
41. Manallack DT, Crosby IT, Khakham Y, Capuano B: Platensimycin: a
promising antimicrobial targeting fatty acid synthesis. Curr Med Chem
2008, 15:705–710.
42. Du Q, Wang H, Xie J: Thiamin (vitamin B1) biosynthesis and regulation: a
rich source of antimicrobial drug targets? Int J Biol Sci 2011, 7:41–52.
43. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M:
Discovery of selective menaquinone biosynthesis inhibitors against
Mycobacterium tuberculosis. J Med Chem 2012, 55:3739–3755.
44. Kronenberger T, Schettert I, Wrenger C: Targeting the vitamin
biosynthesis pathways for the treatment of malaria. Future Med
Chem 2013, 5:769–779.
45. Bermingham A, Derrick JP: The folic acid biosynthesis pathway in
bacteria: evaluation of potential for antibacterial drug discovery.
Bioessays 2002, 24:637–648.
46. Dhar MK, Koul A, Kaul S: Farnesyl pyrophosphate synthase: a key enzyme
in isoprenoid biosynthetic pathway and potential molecular target for
drug development. N Biotechnol 2013, 30:114–123.
47. Lange BM, Rujan T, Martin W, Croteau R: Isoprenoid biosynthesis: the
evolution of two ancient and distinct pathways across genomes.
Proc Natl Acad Sci U S A 2000, 97:13172–13177.
48. Odom AR: Five questions about non-mevalonate isoprenoid biosynthesis.
PLoS Pathog 2011, 7:e1002323.
49. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C,
Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS: DrugBank 3.0: a
comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res
2011, 39:D1035–D1041.
50. Kimmig J: Gerhard Domagk, 1895-1964. Contribution to the chemotherapy
of bacterial infections. Internist (Berl) 1969, 10:116–120.
51. Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides–
small molecules with a multitude of functions. Biochem J 2007,
402:205–218.
52. Sauve AA: NAD + and Vitamin B3: From Metabolism to Therapies.
J Pharmacol Exp Ther 2008, 324:883–893.
53. Khedkar SA, Malde AK, Coutinho EC: Comparative protein modeling of
methionine S-adenosyltransferase (MAT) enzyme from Mycobacteriumtuberculosis: a potential target for antituberculosis drug discovery. J Mol
Graph Model 2005, 23:355–366.
54. Perez-Leal O, Moncada C, Clarkson AB, Merali S: Pneumocystis
S-adenosylmethionine transport: a potential drug target. Am J Respir
Cell Mol Biol 2011, 45:1142–1146.
55. Peleg AY, Hooper DC: Hospital-acquired infections due to Gram-negative
bacteria. N Engl J Med 2010, 362:1804–1813.
56. Chopra I, Schofield C, Everett M, O’Neill A, Miller K, Wilcox M, Frere JM,
Dawson M, Czaplewski L, Urleb U, Courvalin P: Treatment of health-care-
associated infections caused by Gram-negative bacteria: a consensus
statement. Lancet Infect Dis 2008, 8:133–139.
57. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R,
Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H,
Ondeyka J, Herath K, Zhang C, Hernandez L, Allocco J, Basilio A, Tormo JR,
Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C,
Silver LL: Platensimycin is a selective FabF inhibitor with potent antibiotic
properties. Nature 2006, 441:358–361.
58. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C: Type II fatty
acid synthesis is not a suitable antibiotic target for Gram-positive
pathogens. Nature 2009, 458:83–86.
59. Parsons JB, Broussard TC, Bose JL, Rosch JW, Jackson P, Subramanian C,
Rock CO: Identification of a two-component fatty acid kinase responsible
for host fatty acid incorporation by Staphylococcus aureus. Proc Natl Acad
Sci 2014, 111:10532–10537.
60. Heath RJ, Rock CO: Fatty acid biosynthesis as a target for novel
antibacterials. Curr Opin Investig Drugs 2004, 5:146–153.
61. Spalding MD, Prigge ST: Lipoic acid metabolism in microbial pathogens.
Microbiol Mol Biol Rev 2010, 74:200–228.
62. Cuthbert JA, Lipsky PE: Inhibition by 6-fluoromevalonate demonstrates
that mevalonate or one of the mevalonate phosphates is necessary for
lymphocyte proliferation. J Biol Chem 1990, 265:18568–18575.
63. Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA,
Iordanescu S, So CY, Rosenberg M, Gwynn MN: Identification, Evolution,
and Essentiality of the Mevalonate Pathway for Isopentenyl Diphosphate
Biosynthesis in Gram-Positive Cocci. J Bacteriol 2000, 182:4319–4327.
doi:10.1186/1471-2164-15-958
Cite this article as: Mobegi et al.: From microbial gene essentiality to
novel antimicrobial drug targets. BMC Genomics 2014 15:958.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
